Merck & Co Inc
6MK
Company Profile
Business description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Contact
126 East Lincoln Avenue
RahwayNJ07065
USAT: +1 908 740-4000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
75,000
Stocks News & Analysis
stocks
Undervalued ASX share searches for cost savings
Cost savings from recent acquisition underpin our earnings growth forecasts.
stocks
Chart of the Week: Where we see opportunities after year end market sell-off
The latest insights from our equity research team.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,868.20 | 33.10 | -0.37% |
| CAC 40 | 8,022.69 | 29.82 | -0.37% |
| DAX 40 | 24,130.14 | 32.51 | -0.13% |
| Dow JONES (US) | 48,057.75 | 497.46 | 1.05% |
| FTSE 100 | 9,655.53 | 13.52 | 0.14% |
| HKSE | 25,540.78 | 106.55 | 0.42% |
| NASDAQ | 23,654.15 | 77.67 | 0.33% |
| Nikkei 225 | 50,602.80 | 52.30 | -0.10% |
| NZX 50 Index | 13,403.68 | 32.62 | 0.24% |
| S&P 500 | 6,886.68 | 46.17 | 0.67% |
| S&P/ASX 200 | 8,579.40 | 31.70 | -0.37% |
| SSE Composite Index | 3,900.50 | 9.03 | -0.23% |